CNBC Stock Blog
- Stock Picker: Increase Exposure to Health Care Insurers
- Chipmaker Sees Options Upside After a Strong Sector Report
- Unemployment to Peak at 10.5%: Moody's Economist
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- I'm 'Extremely Bullish' on the Credit Markets: 5-Star Manager
- GE-Vivendi Deal Good for GE Finance, Comcast: Market Pro
- How Long Will This Health Care Firm's Rally Last?
- Dubai a 'Wake Up Call'—Expect Volatility Now: Market Pro
- We're Approaching a Market Bubble: Portfolio Manager
MOST SHARED
- Cisco Has 84% of Tandberg, Won't Extend Bid
- UK Economy Turned, Inflation to Spike: BoE Economist
- Kohlberg Kravis Bidding for Morgan Stanley's CICC Stake
- Case Closed but Woods Scrutiny Continues
- Australia Regulator Opposes Caltex-Exxon Deal
- S&P Stocks Trading at New 52-Week Highs
- Mortgage Applications Up as Rates Continue to Decrease
- Somali Sea Gangs Create Pirate Stock Exchange
- S&P Stocks Trading at New 52-Week Highs
- Whitacre Will Change GM, But Will He Bring Better Results?
- Chipmaker Sees Options Upside After a Strong Sector Report
- Treasury Assistance Comes at High Price For GM
- Unemployment to Peak at 10.5%: Moody's Economist
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Mortgage Applications Up as Rates Continue to Decrease
- Tiger Woods Admits 'Transgressions'; Issues Apology
- Wal-Mart Targets Video Games with Latest Price Cuts
- 'Black Swan' Shuns Public Life Because of Bernanke
- Dubai World To Meet with Creditors Next Week
- FHA to Toughen Mortgage Rules in Lenders Crackdown
- Obama to Send More Troops; Seeks Afghanistan Exit
- Blog: Will Whitacre Bring Better Results to GM?
- Geeks Replacing Swashbucklers on Wall Street
RSS FEED
Text Size 
Cofounder, OptionMonster.com
Shares of Acadia Pharmaceuticals skyrocketed along with heavy options activity at the end of last week.
Acadia [
Loading...
()
] soared 31.15 percent to close Friday's regular session at $3.41 and jumped another 23.75 percent in after-hours trading. Total average volume for all options in the name is just 789 per day, but Friday saw 14,900 trades in calls alone.
The bulk of those contracts was a large spread trading 5,000 times between September 5 and 7.50 calls, according to OptionMonster's tracking systems.
The action was apparently driven by speculation over Acadia's pivotal Phase III trial of pimavanserin in patients with Parkinson's disease psychosis. Topline results from this trial are expected to be reported by the end of the third quarter, and this could be why the institiutional investor elected to play out in the September options.
The company also reports earnings results before the market opens Aug. 3 but, like most biopharmaceuticals, it's doubtful that anything but burn rate will be addressed in that release.
Acadia's options volume was 21 times average Friday, and the stock turnover was 7.7 times the normal level. Among the options, calls outnumber puts by more than 9 to 1.
___________________________
Options Trading School:
___________________________
Acadia Pharmaceuticals Competes With:
AstraZeneca [AZN
Loading...
()
]
Eli Lilly [LLY
Loading...
()
]
Pfizer [PFE
Loading...
()
]
___________________________
___________________________
Jon 'DRJ' Najarian is a professional investor, CNBC contributor, and cofounder of OptionMonster.com.
___________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes